UBE2L3 and acquired polycythemia vera: The IVW MR analysis demonstrated that Ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1) was associated with a decreased risk of AD (OR = 0.909, 95% CI: 0.830–0.996, P = 0.040, detailed in Table S3), similarity, Ubiquitin-conjugating enzyme E2 L3 (UBE2L3) was associated with a decreased risk of PV (OR = 0.799, 95% CI: 0.709–0.990, P < 0.001, detailed in Table S4), no other significant association between UBE2 and PV&AD was observed (Fig. 2 for PV, Fig. 3 for AD).